EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe

Małgorzata Pieniążek iD, Anna Polakiewicz-Gilowska, Justyna Żubrowska, Lenka Rušinová, Hana Študentová, Aleksandra Konieczna, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr und 14 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Małgorzata Pieniążek und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Wroclaw Medical University, Wrocław 50-367, Poland. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Camptothecin, Antibodies, Monoclonal, Humanized, Immunoconjugates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sacituzumab govitecan (SG), an antibody–drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in heavily pretreated metastatic triple-negative breast cancer (mTNBC) in the ASCENT trial. However, real-world data remain limited. This study evaluated the effectiveness and safety of SG in an unselected multinational cohort of patients with mTNBC.

Methods

This retrospective analysis included 303 women who initiated SG treatment between August 2021 and April 2025 across 18 oncology centers in Poland, the Czech Republic and Slovakia, within the Central European Breast Cancer Collaboration (CEBCC-102). Primary endpoints were median progression-free survival (mPFS) and overall survival (mOS). Secondary objectives included response pattern, safety and identification of factors influencing outcomes. Adverse events (AEs) were graded using Common Terminology Criteria for AE, version 5.0, and treatment response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Results

The median follow-up was 8.8 months (IQR 4.5-14.4). The mPFS was 4.4 months, and mOS was 11.3 months. The overall response rate was 30.7%. The most frequent AEs were hematologic: neutropenia (69.0%) and anemia (39.6%). In multivariate Cox analyses, poor ECOG performance status and liver metastases were independently associated with worse outcomes. Diarrhea and hypersensitivity reactions showed favorable prognostic associations.

Conclusions

In this largest real-world cohort, the clinical benefit of SG observed in the ASCENT trial was confirmed under routine practice conditions. Poor performance status and liver metastases predicted inferior outcomes, while certain treatment-related AEs warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCamptothecinAntibodies, Monoclonal, HumanizedImmunoconjugatesHumansFemaleRetrospective StudiesMiddle AgedAgedAdultEurope

Stichwörter der Autor:innen

antibody–drug conjugatemetastatic triple-negative breast cancerprogression-free survivalreal-world datasacituzumab govitecansafety

Substanzen

sacituzumab govitecanCamptothecinAntibodies, Monoclonal, HumanizedImmunoconjugates

Autor:innen und Institutionen

  • Department of Oncology, Wroclaw Medical University, Wrocław 50-367, Poland.
  • Lower Silesian Comprehensive Cancer Center, Wrocław, 53-413 Poland.
  • Breast Cancer Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice 44-102, Poland.
  • Department of Clinical Oncology, Holy Cross Cancer Center, Kielce 25-734, Poland.
  • Department of Oncology, Stefan Kukura Hospital Michalovce, Michalovce 071 01, Slovakia.
  • Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc 779 00, Czech Republic.

ORCID-Profile: Małgorzata Pieniążek

Zitieren

APA

Pieniążek, M., Polakiewicz-Gilowska, A., Żubrowska, J., Rušinová, L., Študentová, H., Konieczna, A., Młodzińska, A., Winsko-Szczęsnowicz, K., Lisik-Habib, M., Pękala, A., Krejčí, D., Šustr, J., Kolářová, I., Danielewicz, I., Szymanik-Resko, M., Soumarová, R., Ciszewski, T., Holánek, M., Czartoryska-Arłukowicz, B., …, & Püsküllüoğlu, M. (2026). Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe. The Oncologist. https://doi.org/10.1093/oncolo/oyag014

Vancouver

Pieniążek M, Polakiewicz-Gilowska A, Żubrowska J, Rušinová L, Študentová H, Konieczna A, et al. Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe. The Oncologist. 2026. doi:10.1093/oncolo/oyag014

BibTeX
@article{Pieniek2026,
  author = {Pieniążek, Małgorzata and Polakiewicz-Gilowska, Anna and Żubrowska, Justyna and Rušinová, Lenka and Študentová, Hana and Konieczna, Aleksandra and Młodzińska, Agnieszka and Winsko-Szczęsnowicz, Karolina and Lisik-Habib, Maja and Pękala, Anika and Krejčí, Daniel and Šustr, Jan and Kolářová, Iveta and Danielewicz, Iwona and Szymanik-Resko, Magdalena and Soumarová, Renata and Ciszewski, Tomasz and Holánek, Miloš and Czartoryska-Arłukowicz, Bogumiła and Łacko, Aleksandra and Smok-Kalwat, Jolanta and Jarząb, Michał and Pacholczak-Madej, Renata and Malejčíková, Miroslava and Bielčiková, Zuzana and Püsküllüoğlu, Mirosława},
  title = {Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag014}
}
Kostenlos starten →